BioCentury
ARTICLE | Clinical News

ALK-Abello's dust mite immunotherapy meets in Phase III trial

June 20, 2013 12:56 AM UTC

ALK-Abello A/S (CSE:ALK-B) said once-daily Mitizax for one year met the primary endpoint in the Phase III MERIT (MT-06) trial to treat house dust mite-induced allergic rhinitis. Mitizax -- a House Dust Mite Allergy Immunotherapy Tablet (HDM AIT) -- reduced average total combined rhinitis symptom and medication use score during the last eight weeks of treatment vs. placebo (p<0.01). The double-blind, European trial enrolled 992 patients.

MERIT is the first of two Phase III trials of HDM AIT conducted by ALK-Abello to treat house dust mite-induced respiratory diseases. Data from the Phase III MITRA trial to treat house dust mite-induced allergic asthma are expected by the end of 3Q13. ALK-Abello plans to submit a European regulatory application for the tablet-based vaccine against biological house dust mite allergen in 2014. ALK-Abello gained DKK22 to DKK437 on Wednesday. ...